In Vivo Studies Show CD137 mAb Agonist Boosts Anticancer Activity of Trastuzumab Genetic Engineering News Rather, the CD137 agonist boosted the ability of NK cells activated using trastuzumab-coated breast cancer to kill rituximab-coated lymphoma cells. Similarly, the CD137 antibody boosted the ADCC activity of NK cells activated by rituximab-coated ... |
